Cemiplimab Studied as Neoadjuvant Therapy for Cutaneous SCC
In phase 2 study, about half of patients with resectable stage II to IV cutaneous squamous cell carcinoma had pathological complete response
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.